NASDAQ:CBMX - CombiMatrix Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.25 0.00 (0.00 %) (As of 09/20/2018 04:20 AM ET)Previous Close$6.25Today's Range$6.25 - $6.2552-Week Range$2.20 - $8.20VolumeN/AAverage Volume119,111 shsMarket Capitalization$18.40 millionP/E RatioN/ADividend YieldN/ABeta0.85 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping. Its prenatal and postnatal microarray focuses on diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features and autism spectrum disorders. It develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (products of conception analysis), prenatal genetics and postnatal developmental disorders. Receive CBMX News and Ratings via Email Sign-up to receive the latest news and ratings for CBMX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A SymbolNASDAQ:CBMX CUSIPN/A Webcombimatrix.com Phone+1-949-7530624 Debt Debt-to-Equity Ratio0.02 Current Ratio3.23 Quick Ratio3.03 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$12.87 million Price / Sales1.43 Cash FlowN/A Price / CashN/A Book Value$1.79 per share Price / Book3.49 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-4,140,000.00 Net Margins-15.20% Return on Equity-43.59% Return on Assets-30.86% Miscellaneous Employees55 Outstanding Shares2,940,000Market Cap$18.40 million CombiMatrix (NASDAQ:CBMX) Frequently Asked Questions What is CombiMatrix's stock symbol? CombiMatrix trades on the NASDAQ under the ticker symbol "CBMX." When did CombiMatrix's stock split? How did CombiMatrix's stock split work? CombiMatrix shares reverse split before market open on Monday, February 1st 2016. The 1-15 reverse split was announced on Wednesday, January 27th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2016. An investor that had 100 shares of CombiMatrix stock prior to the reverse split would have 7 shares after the split. How were CombiMatrix's earnings last quarter? CombiMatrix Corp (NASDAQ:CBMX) issued its quarterly earnings results on Monday, November, 6th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.03. The medical research company had revenue of $4.01 million for the quarter, compared to the consensus estimate of $4.19 million. CombiMatrix had a negative return on equity of 43.59% and a negative net margin of 15.20%. During the same period last year, the company earned ($0.38) earnings per share. View CombiMatrix's Earnings History. Who are CombiMatrix's key executives? CombiMatrix's management team includes the folowing people: Robert Judd Jessup, Chairman of the Board (Age 68)Mark McDonough, President, Chief Executive Officer, Director (Age 46)Scott R. Burell, Chief Financial Officer, Treasurer, Secretary (Age 52)Dirk van den Boom Ph.D., Director (Age 47)Robert E. Hoffman, Independent Director (Age 51)Jeremy M. Jones, Independent Director (Age 75)Lale White, Independent Director (Age 60) Has CombiMatrix been receiving favorable news coverage? News stories about CBMX stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. CombiMatrix earned a coverage optimism score of 0.18 on Accern's scale. They also gave news coverage about the medical research company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for CombiMatrix. How do I buy shares of CombiMatrix? Shares of CBMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CombiMatrix's stock price today? One share of CBMX stock can currently be purchased for approximately $6.25. How big of a company is CombiMatrix? CombiMatrix has a market capitalization of $18.40 million and generates $12.87 million in revenue each year. CombiMatrix employs 55 workers across the globe. How can I contact CombiMatrix? CombiMatrix's mailing address is 310 Goddard Ste 150, IRVINE, CA 92618-4617, United States. The medical research company can be reached via phone at +1-949-7530624. MarketBeat Community Rating for CombiMatrix (NASDAQ CBMX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 73 (Vote Outperform)Underperform Votes: 69 (Vote Underperform)Total Votes: 142MarketBeat's community ratings are surveys of what our community members think about CombiMatrix and other stocks. Vote "Outperform" if you believe CBMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/20/2018 by MarketBeat.com StaffFeatured Article: What is Considered a Good Return on Equity (ROE)?